Idarucizumab administration in emergency situations: the Munich Registry of Reversal of Pradaxa® in clinical routine (MR REPAIR)-Reference-Cited by-同舟云学术

Idarucizumab administration in emergency situations: the Munich Registry of Reversal of Pradaxa® in clinical routine (MR REPAIR)

Published:2019-08-02 Issue:11 Volume:266 Page:2807-2811
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Küpper Clemens^ORCID,Feil Katharina,Klein Matthias,Feuerecker Regina,Lücking Marc,Thanbichler Florian,Dietrich Dennis,Zerkaulen Irene,Jandl Mitja,Marziniak Martin,Poppert Holger,Wunderlich Silke,Topka Helge,Dieterich Marianne,Kellert Lars

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

http://link.springer.com/content/pdf/10.1007/s00415-019-09492-w.pdf

Reference10 articles.

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, R-LS Committee Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151

2. Giannandrea D, Caponi C, Mengoni A, Romoli M, Marando C, Gallina A, Marsili E, Sacchini E, Mastrocola S, Padiglioni C, Mazzoli T, Cenciarelli S, Ricci S (2019) Intravenous thrombolysis in stroke after dabigatran reversal with idarucizumab: case series and systematic review. J Neurol Neurosurg Psychiatry 90:619–623

3. Kermer P, Eschenfelder CC, Diener HC, Grond M, Abdalla Y, Althaus K, Berrouschot J, Cangur H, Daffertshofer M, Edelbusch S, Groschel K, Haase CG, Harloff A, Held V, Kauert A, Kraft P, Lenz A, Mullges W, Obermann M, Partowi S, Purrucker J, Ringleb PA, Rother J, Rossi R, Schafer N, Schneider A, Schuppner R, Seitz RJ, Szabo K, Wruck R (2017) Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—a national case collection. Int J Stroke 12:383–391

4. Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI (2017) Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med 377:431–441

5. Sanak D, Jakubicek S, Cernik D, Herzig R, Kunas Z, Mikulik R, Ostry S, Reif M, Rohan V, Tomek A, Veverka T (2018) Intravenous thrombolysis in patients with acute ischemic stroke after a reversal of dabigatran anticoagulation with idarucizumab: a real-world clinical experience. J Stroke Cerebrovasc Dis 27:2479–2483

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes;Thrombosis Research;2023-08

2. Outcome after intracranial hemorrhage under dabigatran and reversal with idarucizumab versus under vitamin-K-antagonists – the RIC-ICH study;Frontiers in Neurology;2023-07-24

3. Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants;JAMA Neurology;2023-03-01

4. Standard operating procedure for idarucizumab reversal of dabigatran anticoagulation in ischemic and hemorrhagic stroke;Journal of Thrombosis and Thrombolysis;2023-02-04

5. Urgent procedures or surgeries in patients receiving oral anticoagulants: a systematic literature review;Journal of Thrombosis and Thrombolysis;2022-12-03